Trial Profile
Efficacy, Safety, Tolerability And Pharmacokinetics Of Tofacitinib For Treatment Of Systemic Juvenile Idiopathic Arthritis (Sjia) With Active Systemic Features In Children And Adolescent Subjects
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 22 Mar 2024
Price :
$35
*
At a glance
- Drugs Tofacitinib (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 19 Mar 2024 Planned End Date changed from 26 Mar 2024 to 27 Mar 2024.
- 19 Mar 2024 Planned primary completion date changed from 26 Mar 2024 to 27 Mar 2024.
- 16 Feb 2024 Status changed from recruiting to active, no longer recruiting.